Validation of TAD in HER-2 with More Than 2 Lymph Nodes

Inclusion Criteria: * ECOG 0-1 (physical condition: able to walk and live a normal life) * Patients with early-stage breast cancer (BC) with histopathological diagnosis of HER2+ and axillary involvement. Patients with either positive or negative hormonal receptor expression will be included. * Patients must have marked the pathological axillary lymph node. * Any number of affected or suspicious lymph nodes at diagnosis is allowed. * Patients will receive appropriate neoadjuvant treatment based on a combination of chemotherapy and anti-HER2 therapy. • After neoadjuvant treatment and prior to surgery, radiological response will be assessed. * No relevant comorbidities, adequate liver and kidney function, and no contraindications to receive neoadjuvant treatment followed by surgery and radiotherapy. Exclusion Criteria: * Patients with inoperable breast cancer. * Patients with a diagnosis of inflammatory breast cancer. * Patients without a diagnostic biopsy of the suspicious lymph node or the presence of axillary conglomerate.